The 8th Edition TNM Stage Reclassification of T4 Non-Small Cell Lung Cancer: A Granular Examination of Short and Long-Term Outcomes.

[1]  J. Bosch-Barrera,et al.  PL03.12 Progression Free Survival and Overall Survival in NADIM II Study , 2022, Journal of Thoracic Oncology.

[2]  N. Girard,et al.  Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. , 2022, The New England journal of medicine.

[3]  O. Riesterer,et al.  Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial. , 2021, The Lancet. Oncology.

[4]  S. Novello,et al.  Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era. , 2021, Lung cancer.

[5]  Jiayan Chen,et al.  Choice of Treatment for Patients With Non–small-cell Lung Cancer >5 cm Between Surgery Alone and Surgery Plus Adjuvant Radiotherapy , 2021, Frontiers in Surgery.

[6]  D. Wankhede.  Evaluation of Eighth AJCC TNM Sage for Lung Cancer NSCLC: A Meta-analysis , 2020, Annals of Surgical Oncology.

[7]  C. Towe,et al.  Neoadjuvant treatment is associated with superior outcomes in T4 lung cancers with local extension. , 2020, The Annals of thoracic surgery.

[8]  Cheng-long Huang,et al.  PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer. , 2019, Lung cancer.

[9]  I. Zlobec,et al.  Comparison of the 7th and 8th Edition of the UICC/AJCC TNM Staging System in Primary Resected Squamous Cell Carcinomas of the Lung—A Single Center Analysis of 354 Cases , 2019, Front. Med..

[10]  Yong-Hee Kim,et al.  Validation of the 8th edition of the TNM staging system in 3,950 patients with surgically resected non-small cell lung cancer. , 2019, Journal of thoracic disease.

[11]  A. Marchetti,et al.  Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM) , 2019, Tumori.

[12]  E. Thunnissen,et al.  A Population‐Based Study of Outcomes in Surgically Resected T3N0 Non–Small Cell Lung Cancer in The Netherlands, Defined Using TNM‐7 and TNM‐8; Justification of Changes and an Argument to Incorporate Histology in the Staging Algorithm , 2019, Journal of Thoracic Oncology.

[13]  Dae Joon Kim,et al.  Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer. , 2018, Journal of thoracic disease.

[14]  Jun Wang,et al.  Validation of the Eighth Edition of the TNM Staging System for Lung Cancer in 2043 Surgically Treated Patients With Non–small‐cell Lung Cancer , 2017, Clinical lung cancer.

[15]  Qun Wang,et al.  Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  A. Gazdar,et al.  Evaluation of the 7th and 8th editions of the AJCC/UICC TNM staging systems for lung cancer in a large North American cohort , 2017, Oncotarget.

[17]  P. Dartevelle,et al.  Extended surgery for T4 lung cancer: a 30 years’ experience , 2017, General Thoracic and Cardiovascular Surgery.

[18]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  Ming Chen,et al.  Comparison of the 7th and proposed 8th editions of the AJCC/UICC TNM staging system for non-small cell lung cancer undergoing radical surgery , 2016, Scientific Reports.

[20]  C. Zappa,et al.  Non-small cell lung cancer: current treatment and future advances. , 2016, Translational lung cancer research.

[21]  Baolan Li,et al.  High levels of Phosphatase and Tensin Homolog Expression Predict Favorable Prognosis in Patients with Non-small Cell Lung Cancer , 2015, Cell Biochemistry and Biophysics.

[22]  L. Kachnic,et al.  Impact of neoadjuvant chemoradiotherapy followed by surgical resection on node-negative T3 and T4 non-small cell lung cancer. , 2011, The Journal of thoracic and cardiovascular surgery.

[23]  A. Seely,et al.  Systematic classification of morbidity and mortality after thoracic surgery. , 2010, The Annals of thoracic surgery.

[24]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[25]  W. Weder,et al.  Extended surgical resection in stage III non-small cell lung cancer. , 2010, Frontiers of radiation therapy and oncology.

[26]  S. Ramalingam,et al.  Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. , 2008, The oncologist.

[27]  P. Dartevelle,et al.  Extended operations after induction therapy for stage IIIb (T4) non-small cell lung cancer. , 1994, The Annals of thoracic surgery.